Ideaya biosciences announces clinical program updates for ide397 a potential first-in-class phase 2 mat2a inhibitor targeting mtap-deletion solid tumors

Targeting ide397 phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable mtap lung and bladder cancer patients in h2 2024, including recist 1.1 clinical efficacy waterfall, swim-lane plot, ctdna molecular response analysis, ae profile, pk and pharmacodynamics initiating ide397 phase 2 monotherapy expansion in mtap bladder cancer, in addition to the earlier reported phase 2 expansion in mtap squamous lung cancer activated over 35 clinical trial sites globally across the u.s., canada, europe, and asia pacific to enable potential rapid enrollment for the ide397 phase 2 clinical program south san francisco, calif. , june 24, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq:idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced clinical program updates for ide397, a potential first-in-class phase 2 mat2a inhibitor targeting mtap-deletion solid tumors.
MAT Ratings Summary
MAT Quant Ranking